Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
ResearchTechnology, Healthcare, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New Funding Round
Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.
Updated 4 hours ago
Hillhouse-Backed SMO Stock ClinPlus Climbs 67% on IPO Day
ClinPlus, a Chinese clinic site management company, has completed the initial public offering process and is now the first SMO company to be listed on the Chinese A-share market. After the IPO, Hillhouse is holding 1.5 percent of the company's stock.
Updated 11 hours ago
Lingbo Yihui Raises Tens of Mns of CNY in a Pre-Series A Round
With the full implementation of the marketing authorization holder (MAH) system and the rapid growth in China's medical device industry, the contract research organization (CRO) and contract development and manufacturing organization (CDMO) markets will continue to grow.
Yesterday 09:28 PM